Recent studies have shown that cancer cells, including renal cell carcinoma, melanoma and glioblastoma are vulnerable to ferroptosis [10] [11] [12] [13] [14] [15] [16] . Furthermore therapy-resistant mesenchymal cancer cells exhibit a greater reliance on GPX4 activity for survival 10,17 . These findings have highlighted the therapeutic potential of pro-ferroptotic agents, but it remains unclear whether induction of ferroptosis can be used therapeutically to selectively kill cancer cells in vivo 1 . A major challenge to testing this hypothesis has been the absence of selective ferroptosis-inducing agents, such as GPX4 inhibitors, suitable for use in vivo 18 .
Ferroptosis is a recently described form of iron-dependent, regulated cell death that is associated with elevated lipid hydroperoxides, a form of reactive oxygen species (ROS) [1] [2] [3] [4] [5] [6] . Lipid hydroperoxides arise from enzymatic or spontaneous oxidation of membrane-associated polyunsaturated fatty acids (PUFAs).
The central ferroptotic regulator is glutathione peroxidase 4 (GPX4), which is the only known peroxidase capable of efficiently reducing esterified, oxidized fatty acids into unreactive alcohols 7 . Small molecules that trigger ferroptosis identified thus far include agents that inhibit GPX4 directly, molecules that deplete the GPX4 cofactor glutathione, and compounds that oxidize iron, all of which lead to lipid hydroperoxide accumulation 1, 8 . Elevated lipid hydroperoxides lead to disruption of membrane architecture, production of reactive aldehydes, and ultimately cell death 9 . While the general mechanism of ferroptosis has been described, important details including metabolic features that render some cells susceptible to ferroptosis are not well understood.
RESULTS

Glutathione depletion triggers ferroptosis in TNBC cell lines
Survival of triple-negative breast cancer cells is dependent on the glutathione biosynthetic pathway to reduce ROS levels 21 . The source of ROS, however, has been unclear. Treatment with buthionine sulfoximine (BSO), an inhibitor of the rate-limiting enzyme of glutathione biosynthesis, triggers cell death in BT-549 cells within days of treatment ( Fig. 1a) . Glutathione depletion in some contexts induces cell death via ferroptosis 22 . Ferroptotic cell death is associated with increased lipid peroxidation and can be suppressed by lipophilic antioxidants like ferrostatin-1 (fer-1) and iron chelators 1 . Consistent with ferroptosis, cytotoxicity in BSO-treated BT-549 cells was blocked by fer-1 but not by an inhibitor of apoptotic cell death, the pan-caspase inhibitor Z-VAD-FMK ( Figs. 1a, b) . Similarly, iron chelators deferoxamine (DFO) and deferiprone suppressed BSO-mediated cell death ( Fig. 1c, Supplementary Figure   S1a ). Furthermore, BSO treatment resulted in the accumulation of lipid peroxidation products and this was suppressed by fer-1 (Figs. 1d, e ). Taken together, this demonstrates that glutathione depletion triggers ferroptosis in BT-549 cells and identifies lipid hydroperoxides as the lethal source of ROS underlying glutathione addiction in TNBC cells.
Sensitivity to ferroptosis is associated with the accumulation of PUFAs
Fer-1 suppressed BSO toxicity in half of the TNBC cell lines tested (Fig. 1f) . These "ferroptotic" cell lines (red bars) were also generally more sensitive to ML162, a small molecule inhibitor of GPX4 23 (Welch's t-test, p=0.01, Fig. 1g, Supplementary Figure S1b ). Thus, ferroptosis is a common response to glutathione depletion in a subset of TNBC cells and is associated with a greater dependence on GPX4 activity. Notably, GPX4 transcripts were not differentially expressed between these two sets of cell lines (Supplementary Figure S1c ), suggesting that ferroptotic vulnerability was independent of the level GPX4 expression. We used ANOVA of our prior metabolomic data for these same cell lines to compare levels of individual metabolites 21 between TNBC cell lines susceptible to BSO-mediated ferroptosis and those that are not (as defined in Fig. 1f ), and found that two of the three most significantly differentially expressed metabolites were linoleate (18:2)-substituted phosphatidylcholines, differing only in the identity of their other acyl chain ( Fig. 1h, i) . These membrane phospholipids were more enriched in ferroptotic compared to non-ferroptotic TNBC cell lines. Because PUFAs can be directly oxidized into lipid hydroperoxides, this finding suggested the possibility that elevated PUFA-containing phospholipids may increase vulnerability to ferroptosis and underlie these cells' greater dependence on GPX4 for survival ( Fig. 1g) . Consistent with this, recent studies implicate membrane phospholipids containing residues of arachidonic acid, and adrenic acid as promoters of ferroptosis 19, 24 .
The conjugated PUFA α-eleostearic acid promotes cancer-selective ferroptosis
We postulated that if PUFA levels are limiting for ferroptosis, elevating levels of specific PUFAs might further sensitize TNBC cells to ferroptosis. We tested a variety of PUFA species and identified the conjugated linolenic acid isomer α-eleostearic acid [(9Z,11E,13E)-octadeca-9,11,13-trienoic acid; αESA] ( Fig. 2a) as a fatty acid that enhanced cell death in combination with BSO ( Fig. 2b) . Unexpectedly, αESA also triggered cell death as a single agent and this death was suppressed by fer-1 (Fig. 2b) , the iron chelator deferoxamine ( Fig. 2c ) and by the lipophilic antioxidant vitamin E (Supplementary Figure S2a ) and was associated with an increase in lipid peroxidation products that could be suppressed by fer-1 ( Fig. 2d) .
Neither the pan-caspase inhibitor Z-VAD-FMK nor the necroptosis inhibitor nec-1s blocked αESA-induced cell death (Supplementary Figure S2b , c). Together, these findings demonstrate that αESA can induce ferroptosis as a single agent.
Interestingly, αESA is abundant in certain plants (e.g. bitter melon and the tung tree) 25 and was previously shown to suppress the growth of breast cancer cells in a manner reversible by antioxidants, though the exact mechanism was unclear 26 . The non-transformed MCF-10A breast epithelial cell line was resistant to death by αESA ( Fig. 2e) . By contrast, all eight tested TNBC cell lines were susceptible to cell death by αESA, including cell lines that did not undergo ferroptosis in response to glutathione depletion ( Fig. 1f) , and in all cases death could be prevented by fer-1 (Figs. 2b, f and not shown). Time lapse phase contrast microscopy of αESA-treated BT549 cells (Supplementary Video 1) showed that during the latter part of 24 hours of treatment, otherwise healthy appearing cells undergo a sudden death, morphologically similar to cell death by the canonical ferroptosis inducer ML162 (Supplementary Video 2) and distinct from apoptotic death induced by staurosporine ( Supplementary Video 3) . Cell death by αESA was associated with a large membrane protrusion that ultimately ruptured, accompanied by a cessation of cytoplasmic motility.
Structure-activity analysis of conjugated PUFAs
αESA is a naturally occurring fatty acid with no structural similarity to known ferroptosis inducers.
To characterize structural features of αESA required for ferroptosis, we screened structurally related conjugated and unconjugated PUFAs for death induction in BT549 cells. αESA possesses conjugated double bonds at carbons 9, 11, and 13 with cis, trans, trans stereochemistry, respectively ( Fig. 2g) . We examined cis-trans stereoisomers of αESA and found that isomerization at position 9 (b-eleostearic acid) or at both 9 and 13 positions (catalpic acid) retained cell death activity while isomerization at position 13 alone (punicic acid) led to an ~4-fold reduction in potency. Jacaric acid (conjugated 18:3, cis-8, trans-10, cis-12) showed the most potent ability to kill cells (1.8 µM IC50), demonstrating that shifting the positioning of the double bonds while maintaining the sequential cis, trans, cis stereochemistry of punicic acid, did not disrupt activity. a-Calendic acid (conjugated 18:3, trans-8, trans-10, cis-12), a stereoisomer of jacaric acid, was similarly potent. Thus, cell killing is not strictly dependent on the precise positioning or stereochemistry of double bonds within the fatty acid. A conjugated linoleic acid (18:2), which shares similar position and stereochemistry of its two double bonds with αESA, was a poor inducer of cell death, however, suggesting that third conjugated double bond is required for its activity. Furthermore, all tested non-conjugated PUFAs (e.g. docosahexaenoic, linoleic, and linolenic acids) were less potent single-agent inducers of cell death (Supplementary Figure S2d ) including arachidonic acid (20:4) , which was of interest because it enhances ferroptosis in some contexts 19, 27 . Cell killing by arachidonic acid could not be rescued by fer-1 (Supplementary Figure S2e ). By contrast, jacaric-and catalpic acid-induced death, like that caused by αESA, was suppressed by fer-1 (Supplementary Figure S2f) . Similar results were found in BT-549 cells (Supplementary Figure S2g) , demonstrating the conserved ability of diverse conjugated 18:3 fatty acids to trigger ferroptosis.
αESA is incorporated into diverse cellular lipids αESA, unlike canonical ferroptotic agents, is a fatty acid that could potentially be incorporated as an acyl chain in cellular lipids. To examine how αESA is metabolized, we conducted a mass spectrometrybased lipidomic analysis of MDA-MB-231 cells that were untreated, αESA-treated, fer-1-treated, or treated with both αESA and fer-1 for three hours. While 18:3-containing lipids were extremely rare in untreated cells, αESA-treatment was associated with incorporation of 18:3 acyl chains, into a diverse array of lipid species including phospholipids, cholesterol esters and storage lipids and fer-1 did not dramatically alter the spectrum of lipid classes that incorporated 18:3 acyl chains ( Fig. 2h ; detailed results are presented in Supplementary Table 1 ). The abundance of di-and triacylglycerol lipids increased ~2-fold in αESAand αESA + fer-1-treated cells compared to untreated controls, suggesting that a portion of αESA is incorporated into storage lipids ( Fig. 2i ). All lipid classes significantly altered by αESA treatment were similarly altered by αESA in the presence of fer-1 (Supplementary Table 1 ). αESA-induced lipidomic changes were not simply downstream consequences of ferroptosis since the effects were not replicated by ML162 treatment (Fig. 2h, i) . Together these results demonstrate that αESA is incorporated into cellular fatty acid pools in a largely fer-1-insensitive manner.
Conjugated PUFAs exhibit anti-cancer activity and promote expression of ferroptotic markers in vivo
We used tung oil as an inexpensive and rich source of αESA (80% of all fatty acids in tung oil are αESA 28 ) to assess whether its anti-TNBC activity could be recapitulated in the aggressive MDA-MB-231 orthotopic xenograft model. Once tumors reached ~ 75 mm 3 , mice were treated by oral gavage five times per week with 100 µl tung oil. Control mice received high-oleic (18:1) safflower oil. Body weights of tung oil-treated mice did not differ significantly from controls over the treatment period (not shown). However, tung oil significantly suppressed tumor growth ( Fig. 3a) and endpoint tumor weight ( Fig. 3b ) and also substantially reduced lung metastatic invasion compared to controls ( Figs. 3c, d) . Immunohistochemistry revealed a 10% decrease in Ki67-positive cells in tumors from tung-treated mice compared to controls and a modest, though statistically significant increase in tumor cleaved caspase 3-positive cells, a marker of apoptosis (from 2% to 5%) (Supplementary Figure S3a To provide evidence that the reduction in tumor growth is associated with tumor exposure to αESA, we conducted a lipidomic analysis of αESA-treated and control tumors. The two most differentially expressed lipids between the tumor groups were diacylglycerol (34:3) and triacylglycerol (52:7), which were increased in tung oil-treated tumors by 30% and 60%, respectively (Fig. 3e) . The masses of these lipids are consistent with at least one linolenate moiety, although their precise acyl chain composition was not determined. Notably, the expression of these two lipids was also increased in cells treated with αESA in vitro, compared to untreated cells ( Fig. 3e) . Our findings identify the neutral lipids diacylglycerol (34:3) and triacylglycerol (52:7) as potential biomarkers of tumor exposure to αESA. Further, they suggest that circulating αESA, released from tung oil, is taken up by TNBC tumor cells and incorporated into lipids.
Next, we assessed whether tumors in αESA-treated mice expressed RNA markers of ferroptosis.
We conducted RNA sequencing of three biological replicates each of tumors from treated and control mice and compared the differentially expressed genes with a separate in vitro experiment using cultured MDA-MB-231 cells treated with either αESA, the GPX4 inhibitor ML162, or corresponding vehicle controls.
Using a false discovery rate of 5% and a filter of >2-fold change in RNA expression level, 124 genes were altered in tung oil-treated tumors compared to safflower oil-treated controls ( Fig. 3f) . Significantly, 89 genes (89/122, 73%) altered in tung oil-treated tumors were also altered in αESA-treated cells in culture.
Fisher's exact test showed extremely significant overlap between these gene sets (p=3.2 x 10 -246 ) and all 89 overlapping genes were altered in the same direction (Supplementary Table 2 ). This is consistent with our hypothesis that the inhibition of tumor growth in vivo is related to the cell death caused by αESA in vitro.
Importantly, there was also a highly significant overlap in genes altered by tung oil in vivo, αESA in vitro, and by in vitro treatment with ML162 ( Fig. 3f and Supplementary Table 2 ). Fisher's exact test between any two gene sets demonstrated p-values of < 7.2 x 10 -61 . Furthermore, all of the shared genes were altered in the same direction. These results demonstrate highly concordant gene signatures between tung oil treatment and αESA treatment, consistent with the hypothesis that tumors in tung oil-treated mice are exposed to αESA. Furthermore, the highly significant overlap in the signatures of αESAand ML162-treated cells provide strong evidence that both treatments trigger a similar response.
All three treatments altered a common set of 23 genes ( Fig. 3f and Supplementary Table 2 ) including genes previously identified as increased during ferroptosis including RHOB, SLC2A3, DDIT4 and HMOX1 15, 29 . In addition, the previously reported ferroptosis marker CHAC1 29 was commonly upregulated in both tung-oil treated tumors and αESA-treated cells. 66 genes were altered by both αESA and tung oil but not ML162 ( Supplementary Table 2 ), suggesting a potential source of biomarkers for αESA-induced ferroptosis.
Ferroptosis induction by αESA is not mediated by GPX4 inhibition
Next, we sought mechanistic insights into ferroptosis induction by αESA. One possibility is that αESA could promote the formation of lipid hydroperoxides by inhibiting GPX4 either directly or indirectly.
For example, ML162 and the structurally distinct GPX4 inhibitor RSL3 directly bind and inactivate GPX4 while BSO and erastin indirectly inhibit GPX4 by starving GPX4 of its essential cofactor glutathione 1 .
While BSO treatment suppressed glutathione levels, treatment of cells with αESA for 24 hours did not significantly affect total cellular glutathione levels despite decreasing cell viability ( Fig. 4a ), suggesting that αESA does not trigger ferroptosis by depleting glutathione. Direct GPX4 inhibitors have been shown to reduce GPX4 protein levels 19 . We confirmed this for ML162 and RSL3 but found that αESA or the negative control erastin had no effect on GPX4 levels ( Fig.   4b ), suggesting that αESA does not inhibit GPX4 activity in a similar way. As an alternative approach to determine whether αESA inhibits GPX4 either directly or indirectly, we compared the kinetics of ferroptosis induction in TNBC cells treated with αESA, ML162 and RSL3 alone and in combination. The combination of both GPX4 inhibitors at 500 nM triggered fer-1-suppressible cell death with similar kinetics to either GPX4 inhibitor alone, indicating this dose of inhibitor was sufficient to achieve near maximal GPX4 inhibition (Fig 4c) . In contrast, cell viability was lost significantly more rapidly when cells were co-treated with 500 nM ML162 and 50 µM αESA, a dose of αESA that took longer to induce cell death than either of the GPX4 inhibitors alone. Consistent with ferroptosis, cell death triggered by the combination of ML162 and αESA could be fully rescued by fer-1 (Fig 4c) . The ability of αESA to further enhance the kinetics of cell death under conditions of maximal GPX4 inhibition suggests that αESA and GPX4 inhibitors trigger ferroptosis by distinct mechanisms.
αESA-induced ferroptosis is lipoxygenase and ACSL1-dependent
Ferroptosis is intimately associated with PUFA peroxidation 30,31 . Lipoxygenases have been reported to mediate peroxidation in ferroptosis induced by GPX4 inhibition 24, 27 but non-enzymatic lipid oxidation by Fenton chemistry may also contribute to this process 18, 32 . To assess lipoxygenase contributions to αESA-induced ferroptosis we systematically knocked down lipoxygenase isoforms by RNA interference in two TNBC cell lines. ALOXE3 knockdown most significantly suppressed αESA toxicity in both cell lines ( Fig. 4d, e) , demonstrating a role for this lipoxygenase isoform in αESA-induced death. This finding does not, however, rule out a potential role for non-enzymatic oxidation, since αESA undergoes spontaneous oxidation more rapidly than other unconjugated and conjugated linolenic acids 33,34 .
The first step in esterification of fatty acids into cellular lipids is their conjugation to CoA, catalyzed by enzymes of the acyl-CoA synthetase family. There are five long chain-specific isoforms (ACSLs) and loss of ACSL4 significantly protects cells from ferroptosis induced by direct or indirect inhibition of GPX4 ( Fig. 4f ; 16, 35, 36 ). αESA, however, was similarly toxic to ACSL4-deficient Pfa1 mouse embryonic fibroblast cells and control parental cells ( Fig. 4g ), suggesting a difference in the mechanism of action of αESA and canonical ferroptosis inducers. αESA-induced cell death was rescued by fer-1 treatment in both cell lines, consistent with ferroptosis (Supplementary Figure S4a ). To determine if any ACSL isoforms contribute to ferroptosis induced by αESA, we individually knocked down expression of each of the five ACSL isoforms in BT549 and MDA-MB-231 cells by RNAi. Knockdown of individual ACSL isoforms expressed in each cell line was confirmed by quantitative PCR (Supplementary Figures S4b, c) . As expected, ML162 toxicity was most effectively suppressed by ACSL4 depletion in both cell lines. αESA toxicity, however, was most significantly suppressed by knockdown of ACSL1 (Figs. 4h, i). Thus, αESA differs in its ACSL isoform dependence compared to a conventional ferroptosis inducer, further supporting a mechanism distinct from canonical ferroptosis inducers.
αESA triggers ACSL1-dependent increases in lipid hydroperoxides
As ferroptosis is associated with an accumulation of oxidized phospholipids, we next used liquid chromatography-mass spectrometry (LC-MS) to ask if aESA treatment impacts phospholipid oxidation.
We quantified 141 mono-, di-, and tri-oxygenated lipids across seven lipid classes in BT-549 cells and found the abundance of oxidized lipids was significantly increased in cells treated with αESA (p = 0.02) ( Fig. 5a) . Overall, the amounts of 51 (36%) lipid species were significantly changed and a majority of those were increased (41/51, 80%). The classes with both the highest number and frequency of increased oxidized species were cardiolipins (17/36 47%) and phosphatidylethanolamines (18/40 45%) and included two dioxygenated phosphatidylethanolamine species containing arachidonate residues ( Fig. 5b) that have been previously identified as ferroptotic signals in cells treated with the GPX4 inhibitor RSL3 19 . These results are consistent with our observation of increased lipid peroxidation products in αESA-treated cells ( Fig. 2d) and suggest that oxidized PE and CL phospholipids may contribute to ferroptosis triggered by αESA.
One possible explanation for the ACSL1-dependence of αESA-induced ferroptosis is that ACSL1 mediates the incorporation of αESA into cellular lipids. To test this, we sought to quantify the presence of 18:3 fatty acids in diverse lipid species in αESAand control-treated cells in which ACSL1 expression was silenced ( Fig. 5c ). Total acyl chain length and double bond count were characterized for each lipid species containing two acyl chains (excludes cardolipins) and we focused on 36:6 lipids because this composition is consistent with two αESA acyl chains. Validating this approach, αESA treatment led to a 13-fold increase in total 36:6 lipids ( Fig. 5d) , which were distributed across all examined lipid classes ( Fig. 5e ). Silencing ACSL1 did not affect overall 36:6 lipid levels in αESA-treated cells, demonstrating that ACSL1 is not essential for αESA esterification, although some individual classes exhibited significantly decreased 36:6
lipids. An alternative hypothesis is that ACSL1 depletion suppresses αESA-induced ferroptosis by lessening the accumulation of oxidized lipid species. We quantified oxygenated lipids in αESA-treated cells in which ACSL1 was knocked down ( Fig. 5f) . Of the oxygenated lipids that were significantly increased following incubation with aESA, 10 (10/41, 24%) were responsive to ACSL1 depletion and all were decreased (detailed in Supplementary Figure S5 ), consistent with the idea that decreasing ACSL1 levels may reduce the accrual of specific peroxidized phospholipids that induce ferroptosis in aESA-treated cells. Indeed, we found that some, but not all, aESA-induced, di-oxygenated PE lipids were decreased on ACSL1-silencing ( Fig. 5b) .
Small-molecule enhancers of αESA-induced ferroptosis implicate phospholipase A2 as a suppressor of ferroptosis
Since αESA causes an accumulation of lipid hydroperoxides ( Fig. 5c ) without decreasing GPX4 ( Fig. 4b) , its toxicity might be enhanced in combination with GPX4 inhibitors. Consistent with this, low doses of BSO, which on their own do not affect cellular viability, enhanced αESA toxicity in vitro (Fig.   2b) . Similarly, treatment of mice with BSO at a dose that does not affect tumor growth on its own 21 , enhanced the anti-tumor activity of tung oil in MDA-MB-231 orthotopic xenografts ( Fig. 6a) . We likewise found that subtoxic doses of αESA enhanced cell killing by the GPX4 inhibitors ML162 and RSL3 in multiple cell lines ( Fig. 6b and Supplementary Figure S6 ). Taken together, our observations are consistent with αESA promoting an increase in lipid hydroperoxides that is opposed by, but ultimately overwhelms GPX4 activity. In addition, they suggest that combining GPX4 inhibitors, should these become clinically viable, with αESA may enhance the anti-tumor activity of αESA.
Finally, we sought to identify other metabolic pathways that might modulate ferroptosis in TNBC cells. We conducted a multi-dose screen of 126 known small molecule inhibitors of diverse metabolic pathways for their ability to modify the toxicity of glutathione depletion in MDA-MB-231 cells. Both enhancers and suppressors of BSO toxicity were identified, including previously reported enhancers of ferroptosis, auranofin 37, 22 , and sorafenib 29 (Fig. 6c) . Among the most potent enhancers was the multitargeting compound RHC-80267. As a single agent, RHC-80267 only weakly induced cell death ( Fig. 6d,   e ). In combination with subtoxic BSO, however, RHC-80267 induced fer-1 suppressible cell death, demonstrating a synthetic lethal interaction between these two compounds ( Fig. 6e) . In untransformed MCF-10A cells BSO did not enhance RHC-80267 toxicity (Fig. 6d) . RHC-80267-induced cell death was also enhanced by αESA in multiple cell types and could be fully rescued by fer-1 ( Fig. 6e ; other cell lines not shown). Thus, RHC-80267 is a selective enhancer of ferroptosis triggered by either αESA or canonical ferroptosis inducers.
One target of RHC-80267 is diacylglycerol lipase 22 but knock down of DAGL1 and DAGL2 isoforms individually and together did not affect αESA potency (not shown). RHC-80267 also exhibits inhibitory activity against phospholipase A2 (PLA2) 38 . To probe a potential role for PLA2 isoforms we used three additional, structurally unrelated PLA2 inhibitors, each of which enhanced ferroptotic death by αESA ( Figs. 6f) . In every case, cell death was suppressed by fer-1. These results point to a key role for PLA2 in protecting against both BSO-and αESA-induced ferroptosis. PLA2 isoforms play a role in phospholipid repair by liberating oxidatively damaged fatty acids from membrane phospholipids 39 . Thus, inhibition of PLA2 may promote αESA-induced ferroptosis by allowing the accumulation of oxidized fatty acids in membrane phospholipids.
DISCUSSION
Cancer cells, particularly drug-resistant and metastatic cells are vulnerable to oxidative stress and depend on antioxidant pathways for their survival 10, [40] [41] [42] [43] [44] [45] . This metabolic liability could potentially be exploited by two complementary therapeutic approaches, inhibiting anti-oxidant survival pathways or promoting oxidative stress. Consistent with the first strategy, we and others have demonstrated a dependence on glutathione-based anti-oxidant pathways in breast cancer 21, 42, 46, 47 . Here, we demonstrate the feasibility of the second strategy, enhancing oxidative stress using conjugated linolenic acids to trigger the production of reactive hydroperoxides, a key mediator of ferroptosis.
GPX4 acts as a central regulator of ferroptosis by preventing the accumulation of phospholipid hydroperoxides. Existing small-molecule inducers of ferroptosis directly or indirectly inhibit GPX4 activity, leading to the accumulation of lipid peroxides produced endogenously. We show here that conjugated linolenic fatty acids provide a distinct mechanism to initiate ferroptosis in which these oxidizable fatty acids increase the production of lipid peroxides that overwhelm GPX4 activity.
Furthermore, the combination of these two approaches robustly enhances cell death both in vitro and in vivo ( Fig. 4c, Figs. 6a, b) . Supporting a distinct mechanism of action, the pro-ferroptotic activity of αESA relies on a subset of ACSL and lipoxygenase isoforms that is at least partially distinct from those exploited by canonical ferroptosis inducers. Despite these mechanistic differences, αESA and conventional ferroptosis inducers both lead ultimately to an increase in lipid peroxides (Figs. 1e, 2d ) and induce a similar transcriptional response ( Fig. 3f ), suggesting a convergent mechanism of lethality. While GPX4 inhibition allows the accumulation of endogenous lipid hydroperoxides, αESA is incorporated into membrane lipids, increasing levels of oxidizable PUFAs, and enhancing overall lipid oxygenation. GPX4 deletion in adult mice leads to acute renal failure and death 48 , suggesting that the therapeutic window for clinical GPX4 inhibitors, should they become available, may be narrow. By contrast, tung oil and αESA (unpublished data) appear to be well tolerated in mice. Thus, these findings expand our understanding of the pathways that regulate ferroptosis and provide a new approach for exploiting ferroptosis therapeutically.
Our metabolic inhibitor screen uncovered a potential role for PLA2 in preventing ferroptosis ( Fig.   6 ), consistent with a recent study that identified secreted PLA2 as a suppressor of lipotoxic stress in breast cancer cells 49 . Inhibitors of PLA2 potentiate ferroptosis by both αESA (Fig. 6f ) and canonical ferroptosis inducers ( Fig. 6d) , possibly by preventing oxidatively damaged fatty acyl chains from being liberated from membrane lipids 39 . This finding suggests that PLA2 inhibitors might enhance the therapeutic efficacy of conjugated linolenic acids or canonical ferroptosis inducers in cancer. PLA2 isoforms constitute a large family of enzymes with potential functional redundancy, making it challenging to identify whether specific isoforms protect against ferroptosis. Nevertheless, this finding supports an emerging model in which dynamic remodeling of membrane fatty acids can modulate cellular vulnerability to PUFA oxidation 50 .
There are two major limitations to translating ferroptosis into a therapeutic modality, the lack of orally available ferroptosis inducers and the absence of robust biomarkers of ferroptosis for use in vivo. We discovered that tung oil, a naturally rich source of αESA, suppresses xenograft tumor growth and metastasis and provide evidence that this activity is mediated by ferroptosis. These results identify tung oil as an inexpensive and bioavailable agent potentially suitable for clinical ferroptosis induction. Moreover, its lack of toxicity and positive interactions with other pro-ferroptotic agents, reported here, suggest opportunities for combination therapy. Finally, we identified a set of genes whose expression is altered in cells undergoing αESAand tung oil-induced ferroptosis as potential biomarkers of ferroptosis and a source of candidate genes that may contribute to this cell death mechanism.
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Grossmann supplemental glutamine, and 100 µg/mL penicillin/streptomycin with the exception of BT-20, which was cultured in MEM with the same supplements. MCF-10A cells were cultured in high calcium medium with 5% horse serum as described 51 . Mouse embryonic fibroblast (Pfa1) Acsl4-deficient cells were described previously 16 . Cells were cultured in a humidified incubator at 37 °C with 5% CO2. Cell lines are periodically tested for Mycoplasma contamination using DAPI (4',6-diamidino-2-phenylindole) to stain DNA.
Statistical Analysis
Metabolite profiling data shown in Figure 1h were analyzed using lipid identification software based on LipidXplorer 54, 55 . Data post-processing and normalization were performed using an in-house developed data management system (Lipotype). Only lipid identifications with a signal-to-noise ratio >5, and a signal intensity 5-fold higher than in corresponding blank samples were considered for further data analysis.
Live Cell Imaging
For the time lapse imaging, BT-549 cells were seeded in a 6-well plate at 125,000 cells/well. After 24 hours, stauroporine (500 nM), aESA (25 µM), or ML162 (500 nM) were added along with 2 mM HEPES (pH 7.4) and then each well was overlaid with mineral oil and placed in a temperature-controlled imaging chamber (37 °C). Three fields in each well were imaged every 10 minutes for a 24-hour period using a Nikon Eclipse TE300 inverted microscope equipped with a Nikon Plan Fluor 10x NA 0.30 objective and a QImaging Retiga EXi camera and using MetaVue software. Movies were assembled using the Fiji implementation of ImageJ 56 . For photomicrographs, cell images were taken using a Nikon Eclipse TE2000 inverted microscope equipped with Nikon Plan Fluor 10x NA 0.30 objective using Metavue (MetaMorph) or Ocular (QImaging) software. The micrographs shown in Figure S2b were captured using the EVOS XL Core Imaging System (ThermoFisher Scientific) with the 10x objective.
Detection of lipid peroxidation products
The (ACGTCAAATTCGATATGTTCAGC, AAGTTCCACTTGATGGCATTTC). 36B4 was used as the normalizer (CCCATTCTATCATCAACGGGTACAA, CAGCAAGTGGGAAGGTGTAATCC).
RNAseq
Total RNA was isolated using the RNeasy kit (Qiagen) from three independent replicates of MDA-MB-231 cells incubated for 5 hours with ML162 (125 nM) and aESA (100 µM) and 2 replicates for the control incubated with the vehicle for aESA (methanol). Three biological replicate tung-oil or control MDA-MB-231 xenograft tumor samples were homogenized in ice-cold PBS using a dounce homogenizer and total RNA was isolated using the RNeasy kit (Qiagen). The stranded mRNA-seq library was generated from 1000 ng of total RNA from each sample using Truseq stranded mRNA library kit (Illumina) according to the product instructions. In short, mRNAs were enriched twice via poly-T-based RNA purification beads, and subjected to fragmentation at 94 °C for 8 minutes via the divalent cation method. The first strand cDNA was synthesized by SuperscriptII (ThermoFisher Scientific) and random primers at 42 °C for 15 mins, followed by second strand synthesis at 16 °C for 1 hour. During second strand synthesis, the dUTP was used to replace dTTP, thereby the second strand was quenched during amplification. A single 'A' nucleotide is added to the 3' ends of the blunt fragments at 37 °C for 30 minutes. Adapters with illuminaP5, P7 sequences as well as indices were ligated to the cDNA fragment at 30 °C for 10 minutes. After Ampure bead (BD) purification (Beckman Coulter), a 15-cycle PCR reaction was used to enrich the fragments. PCR was set at 98 °C for 10 s, 60 °C for 30 s and extended at 72 °C for 30 s. Libraries were again purified using AmPure beads, checked for quality check with a Bioanalyzer (Agilent Technologies) and quantified with Qubit (Invitrogen). Sample libraries were subsequently pooled and loaded to the HiSeq2500 and sequenced using a Hiseq rapid SRcluster kit and HiSeq rapid SBS kit (Illumina). Single 50bp reads were generated for the bioinformatic analysis. Raw sequence reads were aligned to the human genome (hg38) using the Tophat algorithm 57 and Cufflinks algorithm 58 was implemented to assemble transcripts and estimate their abundance. Cuffdiff 59 was used to statistically assess expression changes in quantified genes in different conditions. 
Cell viability assays and reagents
Glutathione measurements
Cellular glutathione was quantified using the GSH/GSSG-Glo kit (Promega) according to the instructions provided by the manufacturer. Drug-treated samples were normalized to parallel cell viability measurements using the CellTiter-Glo assay (Promega).
Quantitation of GPX4 protein levels
MDA-MB-231 were seeded at a density of 170,000 cells/well of a 6-well plate. After 24 hours, 
Screen of metabolic modulators
A cell viability screen was performed using a library of 126 small molecule modulators of metabolic pathways (Focus Biomolecules IntelliScreen Cellular Metabolism Library). MDA-MB-231 cells were plated in 384-well format at a density of 1250 cells per well in the presence or absence of 10 µM BSO.
Compounds (5 doses per compound) were delivered by pin transfer 24 hours after cell plating. After 72 hours, cell viability was measured using CellTiter-Glo Luminescent Cell Viability Assay (Promega)
according to the manufacturer's instructions. Data were normalized to vehicle-treated controls and were fitted to IC50 curves using GraphPad Prism (Version 8).
Mouse xenografts
Orthotopic xenografts were generated by implanting 2.5 million MDA-MB-231 cells in 100 µL phosphatebuffered saline (PBS) mixed with 100 µL growth factor-reduced Matrigel (Corning) bilaterally into the fourth inguinal fat pad of four-to six-week-old female NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice. After 14 days, when tumors were roughly 50 mm 3 , animals were randomized into treatment groups. Mice were treated on weekdays with either safflower oil (Whole Foods 365) and Tung oil (Sigma-Aldrich 440337) at a dose of 100 µL administered by oral gavage. L-BSO (Sigma) was administered via the drinking water (20 mM) ad libitum as previously reported 21, 60 . The Fox Chase Cancer Center Institutional Animal Care and Use Committee reviewed and approved all animal procedures as compliant with relevant ethical regulations.
Tissue preparation, histology, and immunohistochemistry
Tumor sections and lung sections were fixed in 10% formalin for 24-48 hours, dehydrated and embedded in paraffin. Immunohistochemical staining was performed by standard methods. Tissue sections were incubated with primary antibodies to anti-human Ki-67 (Clone MIB-1, DAKO) and cleaved caspase-3 (Cell Signaling; #9661) at 4 °C in a humidified chamber overnight. To quantify lung metastases, lungs from three mice per treatment group were fixed, sectioned and hematoxylin and eosin stained. Ten equally sized regions (2 from each lobe) were randomly selected and scored manually for area occupied by cancerous tissue. Micrographs were captured with a Nikon DS-Fi1 camera (Melville, NY, USA) on a Nikon Eclipse 50i microscope and quantified using a ScanScope CS5 slide scanner (Aperio).
Data Availability
All data generated or analyzed during this study are included in this published article (and its supplementary information files) or are available from the corresponding author on reasonable request. Supplementary Table S3 . CEBPB  CHMP1B  CLK1  DDIT4  DUSP1  DUSP10  GDF15  GEM  HMOX1  IER5L  IL11  INSIG1  KRTAP2-3  OSR1  PNRC1  RHOB  RRAD  SIK1B  SLC2A3  TGIF1 f p = 0.046 ns p = 0.01 p = 0.008 p = 0.03 p = 0.002 p = 0. BT-549 p = 0.02 p = 0.02 p = 0.02 p = 0.03 p = 0.02 p = 0.005 p = 0.009 p = 0.01
